

SSTR Antagonists as Theranostic Option in Merkel Cell Carcinoma

Malte Kircher¹, Adriana Amerein¹, Mareike Augustin², Nic G. Reitsam³, Johanna S. Enke¹, Marianne Patt¹, Georgine Wienand¹, Ralph A. Bundschuh¹, Christian H. Pfob¹, Constantin Lapa¹, and Alexander Dierks¹

¹Department of Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany; ²Department of Dermatology, Faculty of Medicine, University of Augsburg, Augsburg, Germany; and ³Department of Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany

Merkel cell carcinoma is a rare, highly aggressive skin cancer. With multimodal treatment including chemo- and immunotherapy, the 5-y overall survival ranges from 14% to 62%, depending on the disease stage at diagnosis (1). New treatment options are therefore urgently needed. Given the overexpression of somatostatin receptors (SSTRs) due to its neuroendocrine features, SSTR-directed therapy could be a promising target in metastatic Merkel cell carcinoma (2–4).

To further investigate this potential, 2 clinical trials are already ongoing in which peptide receptor radionuclide therapy with SSTR agonists are being studied in combination with immunotherapy (GoTHAM trial, NCT04261855; iPRRT trial, NCT05583708).

Although various agonistic SSTR-targeting tracers have been established for years in metastatic Merkel cell carcinoma and other neuroendocrine tumor entities, tracers with antagonistic receptor interaction are recognized as a new, promising theranostic option, as they can achieve high tumor uptake and prolonged retention as compared with agonists (5).

We report the case of a 77-y-old man with recurrent metastatic Merkel cell carcinoma who underwent PET/CT with the ⁶⁸Ga-labeled SSTR antagonist SSO120 (international nonproprietary name: satoreotide trizoxetan; also known as NODAGA-JR11, OPS202, and IPN01070; injected dose, 160 MBq; scan acquisition,




FIGURE 1. Maximum-intensity projections and axial sections of [⁶⁸Ga]Ga-SSO120 (A) and [¹⁸F]FDG (B) PET/CT. Location of exemplary pelvic (right iliac) lymph node metastasis with SUV_{max} of 11.6 vs. 5.5 on [¹⁸F]FDG PET is indicated by white and black arrows, respectively. Intensity scale bars are SUV. Immunohistochemistry showed high membranous SSTR expression on all tumor cells (score 3+; C).

60 min after injection) (6, 7) to explore the possibility for peptide receptor radionuclide therapy (Fig. 1A). Informed consent was obtained from the patient. Compared with [¹⁸F]FDG PET (Fig. 1B), a more intense tracer uptake and excellent tumor-to-background ratios were observed using [⁶⁸Ga]Ga-SSO120 PET, for example, in a pelvic (right iliac) lymph node metastasis with an SUV_{max} of 11.6 versus 5.5 on [¹⁸F]FDG PET. The average SUV_{max} in the 6 measurable tumor lesions was 13.4 ± 5.0 with [⁶⁸Ga]Ga-SSO120 versus 9.5 ± 4.2 with [¹⁸F]FDG PET. Given the still-localized tumor stage, the patient underwent surgery. High membranous SSTR expression on all tumor cells was confirmed by immunohistochemistry (score 3+; Fig. 1C).

In conclusion, PET/CT with SSTR antagonists could serve as a noninvasive read-out for tumor biology and allow selection of candidates for SSTR-directed peptide receptor radionuclide therapy. Further research, especially regarding advantages over agonistic vectors, is highly warranted.

Received Nov. 25, 2023; revision accepted Jan. 11, 2024.

For correspondence or reprints, contact Malte Kircher (malte.kircher@uk-augsburg.de).

Published online Feb. 8, 2024.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: <https://creativecommons.org/licenses/by/4.0/>. Details: <http://jnm.snmjournals.org/site/misc/permission.xhtml>.

COPYRIGHT © 2024 by the Society of Nuclear Medicine and Molecular Imaging. DOI: 10.2967/jnumed.123.267124

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma. *Nat Rev Dis Primers*. 2017;3:17077.
2. Buder K, Lapa C, Kreissl MC, et al. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. *BMC Cancer*. 2014;14:268.
3. Meier G, Waldherr C, Herrmann R, Maecke H, Mueller-Brand J, Pless M. Successful targeted radiotherapy with ⁹⁰Y-DOTATOC in a patient with Merkel cell carcinoma. *Oncology*. 2004;66:160–163.
4. Askari E, Moghadam SZ, Wild D, et al. Peptide receptor radionuclide therapy in Merkel cell carcinoma: a comprehensive review. *J Nucl Med Technol*. 2023;51:22–25.
5. Fani M, Mansi R, Nicolas GP, Wild D. Radiolabeled somatostatin analogs: a continuously evolving class of radiopharmaceuticals. *Cancers (Basel)*. 2022;14:1172.
6. Zhu W, Cheng Y, Wang X, et al. Head-to-head comparison of ⁶⁸Ga-DOTA-JR11 and ⁶⁸Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. *J Nucl Med*. 2020;61:897–903.
7. Nicolas GP, Schreiter N, Kaul F, et al. Sensitivity comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. *J Nucl Med*. 2018;59:915–921.